Phase
            III
            randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (
            RADPAC
            )

User: Guest

Document type:: Zeitschriftenaufsatz
Author(s):: Lorenzen, Sylvie; Knorrenschild, Jorge Riera; Pauligk, Claudia; Hegewisch‐Becker, Susanna; Seraphin, Jörg; Thuss‐Patience, Peter; Kopp, Hans‐Georg; Dechow, Tobias; Vogel, Arndt; Luley, Kim Barbara; Pink, Daniel; Stahl, Michael; Kullmann, Frank; Hebart, Holger; Siveke, Jens; Egger, Matthias; Homann, Nils; Probst, Stephan; Goetze, Thorsten Oliver; Al‐Batran, Salah‐Eddin
Title:: Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen ( RADPAC )
Journal title:: International Journal of Cancer
Year:: 2020
Fulltext / DOI:: doi:10.1002/ijc.33025
Publisher:: Wiley
E-ISSN:: 0020-71361097-0215
Date of publication:: 07.05.2020
BibTeX

Occurrences: